US Outcomes-Based, Innovative Contracting (OBIC) Tracker – May 2017 Announce three new contracts in one month Becomes the #1 payer for publishing OBICs moves into 2 nd place with it’s latest contracts for: Amgen remains #1 manufacturer publishing OBICs
17
Embed
US Outcomes-Based, Innovative Contracting (OBIC) Tracker ...€¦ · US Outcomes-Based, Innovative Contracting (OBIC) Tracker –May 2017 Announce three new contracts in one month
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
US Outcomes-Based, Innovative Contracting (OBIC) Tracker – May 2017
Announce three new contracts in one month
Becomes the #1 payer for publishing OBICs
moves into 2nd place with it’s latest contracts for:
Amgen remains #1 manufacturer publishing OBICs
Updated: 05/31/2017
The US OBIC TrackerOutcomes Based, Innovative Contracting
About Stisali & The US OBIC Tracker
The US OBIC Tracker
A ground-breaking, new, complimentary service to track and analyze the quickly evolving horizon of
US value based agreements. The tracker monitors the who, what and when of OBIC, ensuring you
keep up to date on the industry’s very latest developments. In addition, Stisali’s payer experts
provide analysis on the market drivers for OBIC and the levers adopted. The tracker will be
published routinely and inline with market developments.
Subscribe
To receive your own copy of the US OBIC Tracker please email [email protected] .
Base data collected using desk research on all publicly available information relating to outcomes based, innovative contracts in the USA from 1998 to May 25th 2017.
OBIC is classified as either:
• Outcome payment – reimbursement tied to a clinical &/or process outcome at either individual patient or population level i.e. reduction in a clinical indicator such as HbA1C
and/or
• Conditional payment – payment is contingent on specific short-term health outcome or evidence target i.e. Persistence
and/or
• Innovative contracts i.e. indication based pricing, free stock etc.
Data only relates to bio and pharmaceutical products, not devices and diagnostics
Data does not include traditional, straight discount & rebate deals based on volume &/or usage
Analysis – Read Me
Date – relates to the first evidence of public notification of the OBIC, not contract commencement
Not Disclosed, Undisclosed & ND – insufficient information provided to complete the field
Payer – the name of the payer organization which initiated the contract
OBIC Type – a classification nomenclature applied by Stisali to represent the mechanism used in the contract
Primary Payer Landscape – a classification nomenclature applied by Stisali’s payer team to represent the predominant payer driver for that product &/or drug class at that time of the contract announcement
For any questions relating to the data and/or analysis please contact [email protected]
About Stisali & The US OBIC Tracker
Stisali
Stisali are managed market experts, exclusively specializing in risk share and outcomes based, innovative contracting
(OBIC). The company uses insight and experience gained from mature managed markets to create highly effective
value based agreements for US manufacturers. www.stisali.com
Subscribe
To receive your own copy of the US OBIC Tracker please email [email protected] .